BAA-75N93022R00021: Development of Radiation/Nuclear Medical Countermeasures (MCMs) or Biodosimetry Devices

Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases          Visit us on the Web   BAA-75N93022R00021: Development of Radiation/Nuclear Medical Countermeasures (MCMs) or Biodosimetry Devices   The goal of this BAA is to solicit proposals for (a) the development of medical countermeasures (MCMs) against radiation injury or, (b) biodosimetry approaches targeting radiation-specific biomarker identification and/or device development to predict acute and/or delayed damage to specific organs and tissues beyond dose assessment. This BAA is intended to support research and development of promising new approaches to mitigate or treat tissue injuries arising from unintended exposure to ionizing radiation, which may include biologics (e.g., cytokines and free radical scavengers), cellular therapies, or drugs (e.g., anti-inflammatory agents, antibiotics, and anti-fibrotics). The lead MCM to be supported by this initiative should be easy to distribute and use in a mass casualty incident (i.e., preferred routes of administration are oral, subcutaneous, inhalation, transdermal, topical, or intramuscular). Cellular therapies, which may require intravenous administration, may also be supported. For H-ARS products, candidates must demonstrate advantages over existing FDA-approved H-ARS MCMs to be considered responsive to the BAA (e.g., efficacious when administered at 48 hours post-radiation exposure or later, more advantageous route of administration for a mass-casualty scenario, lower cost, improved mass casualty-amenable storage, etc.). This BAA is intended to support further development of biodosimetry biomarkers (biological indicators of radiation-induced tissue injuries), and/or diagnostic systems (point-of-care field, or definitive care devices) to rapidly assess levels and types of radiation exposure using minimally invasive biological sampling (e.g., a minimal quantity of blood, hair follicles, skin swabs, saliva, serum, or urine; rather than samples like spinal fluid or tissue biopsies).    All Dates/Times are: (UTC-05:00) EASTERN STANDARD TIME, NEW YORK, USA Published Date: Nov 28, 2022 09:13 am EST Offers Due: Feb 27, 2023 03:00 pm EST Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107